Ron Johnson

AbbVie, facing thousands of lawsuits about its AndroGel testosterone supplement, notches a significant win

AbbVie, facing thousands of lawsuits about its AndroGel testosterone supplement, notches a significant win

AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, strokes and other injuries.

A jury decided the North Chicago-based drugmaker was not to blame for the pulmonary embolism suffered by a 72-year-old Arizona retiree who started using AndroGel after seeing TV advertisements promoting testosterone therapy as a fix for fatigue and low sex drive. It marked the first verdict in Chicago federal court to clear AbbVie of any wrongdoing.

The win for AbbVie comes a few months after two separate juries in the same federal courtroom...

39°